CN110339220A - Willow herb extract is used to be promoted the purposes of gene performance amount - Google Patents
Willow herb extract is used to be promoted the purposes of gene performance amount Download PDFInfo
- Publication number
- CN110339220A CN110339220A CN201811315571.9A CN201811315571A CN110339220A CN 110339220 A CN110339220 A CN 110339220A CN 201811315571 A CN201811315571 A CN 201811315571A CN 110339220 A CN110339220 A CN 110339220A
- Authority
- CN
- China
- Prior art keywords
- willow herb
- gene
- purposes
- herb extract
- willow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000008302 Chamaenerion angustifolium Nutrition 0.000 title claims abstract description 75
- 239000000284 extract Substances 0.000 title claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 45
- 244000103926 Chamaenerion angustifolium Species 0.000 title description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 13
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 13
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 13
- 230000028327 secretion Effects 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 206010020649 Hyperkeratosis Diseases 0.000 claims abstract description 5
- 208000001126 Keratosis Diseases 0.000 claims abstract description 5
- 241000721098 Epilobium Species 0.000 claims abstract 20
- 210000004027 cell Anatomy 0.000 claims description 51
- 108010063290 Aquaporins Proteins 0.000 claims description 22
- 102000010637 Aquaporins Human genes 0.000 claims description 22
- 108010076876 Keratins Proteins 0.000 claims description 21
- 102000011782 Keratins Human genes 0.000 claims description 17
- 102100028314 Filaggrin Human genes 0.000 claims description 13
- 102100030944 Protein-glutamine gamma-glutamyltransferase K Human genes 0.000 claims description 13
- 108010058734 transglutaminase 1 Proteins 0.000 claims description 13
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 claims description 12
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 claims description 12
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 claims description 11
- 108060008539 Transglutaminase Proteins 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 8
- 102000002151 Microfilament Proteins Human genes 0.000 claims description 7
- 108010040897 Microfilament Proteins Proteins 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 210000003632 microfilament Anatomy 0.000 claims description 7
- 102000003601 transglutaminase Human genes 0.000 claims description 7
- 101000975474 Homo sapiens Keratin, type I cytoskeletal 10 Proteins 0.000 claims description 6
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 claims description 6
- 101001046960 Homo sapiens Keratin, type II cytoskeletal 1 Proteins 0.000 claims description 6
- 108010070514 Keratin-1 Proteins 0.000 claims description 6
- 108010066321 Keratin-14 Proteins 0.000 claims description 6
- 102000004363 Aquaporin 3 Human genes 0.000 claims description 5
- 108090000991 Aquaporin 3 Proteins 0.000 claims description 5
- 101710088660 Filaggrin Proteins 0.000 claims description 5
- 108010065038 Keratin-10 Proteins 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000000638 solvent extraction Methods 0.000 claims description 5
- 239000003292 glue Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 241000124033 Salix Species 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 abstract description 10
- 230000008591 skin barrier function Effects 0.000 abstract description 8
- 101150071538 AQP gene Proteins 0.000 abstract description 7
- 101150063233 FLG gene Proteins 0.000 abstract description 5
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 31
- 239000000243 solution Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 210000002615 epidermis Anatomy 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 101150058971 KRT10 gene Proteins 0.000 description 2
- 101150040052 KRT14 gene Proteins 0.000 description 2
- 101150056422 Krt1 gene Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 2
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 2
- 101150039702 TGM1 gene Proteins 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 230000037365 barrier function of the epidermis Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- AXPZIVKEZRHGAS-UHFFFAOYSA-N 3-benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one Chemical compound [O-][N+](=O)C1=CC=CC=C1OCC1OC(=O)C(CC=2C=CC=CC=2)C1 AXPZIVKEZRHGAS-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 235000006890 Chamerion angustifolium subsp angustifolium Nutrition 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000219929 Onagraceae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- PZTQVMXMKVTIRC-UHFFFAOYSA-L chembl2028348 Chemical compound [Ca+2].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 PZTQVMXMKVTIRC-UHFFFAOYSA-L 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 238000004781 supercooling Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
The present invention relates to the purposes that the purposes of willow herb extract, especially willow herb extract are used to be promoted gene performance amount.The present invention, which provides a kind of willow herb extract and is used to prepare, promotes TGM, KRT, AQP and FLG gene performance amount, and promotes horn cell secretion sodium hyaluronate and soothe the skin the purposes of sensitive, general red medical composition, effectively horn cell can be maintained to arrange, make keratoderma structural integrity, to promote skin barrier function and skin is made to form more moisturizing factors.Wherein the willow herb extract is that willow herb is extracted with the solvent of water, alcohol or alcohol-water mixture and obtained.
Description
Technical field
The present invention relates to the purposes of willow herb extract, especially a kind of willow herb extract is for promoting transglutaminase
(Transglutaminase, TGM) gene, keratin (Keratin, KRT) gene, aquaporin (Aquaporin, AQP)
The purposes of gene and the medical composition of poly- keratin microfilament (Filaggrin, FLG) gene performance amount.
Background technique
Epidermis is the outermost layer of skin, by being outside inside sequentially cuticula, stratum granulosum, having spinous layer and basal layer, epidermis
Layer, which is mainly continued upward by cylindrical type horn cell undifferentiated in basal layer, to be differentiated to form, this process is known as keratinization.
Water content is high in horn cell, and as cell is metabolized differentiation upwards, horn cell shape can gradually become flat, and nucleus
And born of the same parents' device starts degeneration atrophy, and the dead cell for not having nucleus Yu born of the same parents' device is formed in cuticula.The major function of epidermis is
Make skin moisturizing, and form skin barrier to resist various external injuries, wherein epidermis outermost layer is by a weakly acidic sebum
Film and as the cuticula of brick wall structure is constituted, this barrier can lock the moisture of skin and grease, resist skin surface germ
Invasion, and the confrontation injury such as external foreign matter and ultraviolet light, have very important protective effect to human body.
Cuticula in epidermis, although horn cell is dead cell, its main component is keratin
(keratin), keratin, which can absorb moisture, makes skin keep wet, and horn cell can also secrete such as sodium hyaluronate substance as thin
Matrix, to maintain the structural integrity of epidermis skin barrier, to prevent moisture of skin to scatter and disappear and form complete protection.Work as skin
The stimulations such as the environment and irradiating ultraviolet light of contact supercooling or overheat will lead to horn cell and be unable to maintain that normal metabolism follows
Ring, and make skin epidermis barrier impaired, and allow skin become coarse, dry furfur, it is fragile vulnerable to stimulation, it is sensitive general red and
Skin moisturizing ability can be made to decline, therefore the health of cuticula is for skin moisture-keeping and to resist external injury really very heavy
It wants.
Synthesis is described above, causes skin to become fragile, Yi Min and skin moisturizing because horn cell is impaired to improve
The problem of ability declines, developing a kind of can effectively maintain horn cell arrangement, maintain cuticula structural integrity and to keep cutin thin
The more moisturizing factors of intracrine have its necessity to promote the medical component of skin barrier and moisture-keeping functions really.
Summary of the invention
Edge this, a purpose of the invention is used to prepare promotion transglutaminase providing a kind of willow herb extract
(Transglutaminase, TGM) gene, keratin (Keratin, KRT) gene, aquaporin (Aquaporin, AQP)
The purposes of gene and the medical composition of poly- keratin microfilament (Filaggrin, FLG) gene performance amount.
A further object of the present invention promotes aquaporin in horn cell providing a kind of willow herb extract and be used to prepare
Protein expression medical composition purposes.
A further object of the present invention promotes horn cell secretion sodium hyaluronate providing a kind of willow herb extract and be used to prepare
The purposes of medical composition.
Another object of the present invention soothes the skin sensitive, general red medical group providing a kind of willow herb extract and be used to prepare
Close the purposes of object.
Willow herb extract of the invention is obtained with one willow herb of a solvent extraction, which is water, alcohol or the mixing of alcohol water
The liquid-solid ratio of object, the solvent and the willow herb is 5~20: 1~5, and the extraction step is carried out at 50 DEG C~100 DEG C.
In one embodiment of this invention, which is transglutaminase 1
(Transglutaminase 1, TGM1) gene；The keratin gene includes Keratin 1 (Keratin1, KRT1) gene, angle
Protein 10 (Keratin10, KRT10) gene and Keratin 14 (Keratin14, KRT14) gene；The aquaporin is that water is logical
Road albumen 3 (Aquaporin 3, AQP 3).
In one embodiment of this invention, which can maintain the arrangement of horn cell, make keratoderma knot
Structure is complete.
Meanwhile the present invention is for promoting TGM, KRT, AQP and FLG gene performance amount, and promotion horn cell secretion glass
Uric acid simultaneously soothes the skin sensitive, general red medical composition, also may include that an a effective amount of willow herb extract and one pharmaceutically may be used
The carrier of receiving, the composition are with the presence of powdered, graininess, liquid, glue or paste.
Embodiments of the present invention are further illustrated below in conjunction with schema, and following cited embodiments are to illustrate
The present invention, the range being not intended to limit the invention is any to be familiar with this those skilled in the art, is not departing from the spirit and scope of the present invention
It is interior, when can do it is a little change and retouch, therefore protection scope of the present invention when regard appended claims institute's defender as
It is quasi-.
Detailed description of the invention
Fig. 1 be the embodiment of the present invention willow herb extract in promoted transglutaminase 1 (Transglutaminase 1,
TGM1) gene, Keratin 1 (Keratin1, KRT1) gene, Keratin 10 (Keratin10, KRT10) gene and Keratin 14
The histogram of (Keratin14, KRT14) gene performance amount；
Fig. 2 is the willow herb extract of the embodiment of the present invention in promotion aquaporin 3 (Aquaporin 3, AQP 3) gene
The histogram of performance amount；
Fig. 3 is the willow herb extract of the embodiment of the present invention in poly- keratin microfilament (Filaggrin, FLG) the gene table of promotion
The histogram now measured；
Fig. 4 is that the willow herb extract of the embodiment of the present invention promotes the protein expression of aquaporin in horn cell
Immunofluorescence dyeing figure；
Fig. 5 is the willow herb extract for the embodiment of the present invention in the histogram for the effect for promoting horn cell secretion sodium hyaluronate
Figure；
Fig. 6 be for；The willow herb extract of the embodiment of the present invention is in the histogram for soothing the skin general red effect.
Specific embodiment
The preparation method of the willow herb extract of the invention of embodiment 1
Willow herb (Epilobium angustifolium) is Oenotheraceae (Onagraceae) herbaceos perennial, raw
In 3100~4250 meters of height above sea level of hillside border, the wet meadow of hayashishita and river valley, stem is that vertical is about 1 meter high, leaf be lanceolar and
Without petiole, there is serration at edge, and two sides is by microtriche, and flower spike is long and is purple or pale red, and it is the ideal summer that the florescence, which is 6~August,
Ji Huahui, be currently known willow herb have effects that regulating menstruation and activating blood, swelling and pain relieving, treatment menstruation have some setbacks, fracture, joint sprain.
In an embodiment of the present invention, the whole strain of willow herb is cleaned, takes the extractant of the whole strain of willow herb and water after cleaning with 5
~20: 1~5 liquid-solid ratio mixing after carrying out extraction 0.5~3 hour in a solvent, is added alcohol and removes suspended material, to obtain
Obtain thick extract.It is cooled to room temperature after extraction, by the thick extract via 0.45~0.2 micron of strainer filtering to be filtered
Liquid.Finally, being concentrated under reduced pressure and being added preservative in 45~70 DEG C for the filtrate, willow herb extract of the invention is obtained.
The willow herb extract of the present invention of embodiment 2 promotes TGM1, KRT1, KRT10, KRT14, APQ3 and FLG in horn cell
Gene performance amount
The present invention with mankind's skin keratinocytes primary (human primary epidermal keratinocytes,
HPEK the genetic analysis of TGM1, KRT1, KRT10, KRT14, APQ3 and FLG) are carried out.Mankind's Primary dermal horn cell is purchased from
CELLnTEC company (Switzerland) number HPEK-50, by the cell culture in the horn cell culture solution of serum-free
(keratinocyte-SFM) (Gibco company, number #10724-011, the U.S.).
Mankind's horn cell primary is divided into two groups: (1) experimental group and (2) that willow herb extract of the invention is added are empty
White control group uses RNA extraction agent set group after lysate (lysis buffer) receipts integrated pipe then is added in horn cell
(being purchased from Geneaid company, TaiWan, China, Lot No.FC24015-G) collects the RNA in two groups of horn cells respectively, then
It utilizesIII reverse transcriptase (being purchased from Invitrogene company, the U.S., number 18080-051) is with 2000ng
Extraction RNA be template and with primer generate mRNA reverse transcription corresponding cDNA product, followed by ABI StepOnePlusTM
Real-Time PCR system (Thermo Fisher Scientific company, the U.S.) and KAPA SYBR FAST (purchase
From Sigma company, the U.S., number 38220000000) product after two groups of reverse transcriptions is determined respectively with the combination primer of table one
Measure real time RT polymerase chain reaction (quantitative real-time reverse transcription
Polymerase chain reaction) test, quantitative TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene,
The mRNA performance amount of APQ3 gene and FLG gene, condition are 95 DEG C and react 1 second that 60 DEG C are reacted 20 seconds, and 40 recycle in total,
Middle quantitative value is to take by threshold cycle number (Ct), and the mRNA relative quantity of target gene is to be derived from equation 2-△Ct, wherein
△ Ct=CtTarget gene- CtTBP (TATA binding protein, TATA box binding protein), recycle Excel software into
The non-paired list tail student t-test of row with determine the coefficient of variation with whether statistically with significant difference (* p value <
0.05；P value < 0.01 *；P value < 0.001 * *).
The combination primer of table one, quantitative real time RT polymerase chain reaction
Willow herb extract of the invention is for promoting TGM1, KRT1, KRT10, KRT14, APQ3 and FLG in horn cell
Gene performance effect experimental result it is as shown in Figure 1, Figure 2 and Figure 3, previous research point out transglutaminase
(Transglutaminase1, TGM) can make to form strength bond between the cell membrane of keratinocyte and structural proteins, and can increase
Add the stabilized soil pavement of epidermis；Keratin (Keratin, KRT) will form angle egg microfilament, and poly- keratin microfilament
(Filaggrin, FLG) can help keratin microfilament to be assembled into firm network, provide intensity and elasticity for skin；Aquaporin egg
White (Aquaporin, AQP) can then add the permeability of water in horn cell, to improve the water content of horn cell.Horn cell warp
After the processing of willow herb extract, compared to blank control group, about 1.8 times of TGM1 gene performance amount promotion, KRT1 gene performance amount are mentioned
Rise about 2.4 times, about 2 times of KRT10 gene performance amount promotion, KRT14 gene performance amount promotion about 2.3 times, APQ3 gene performance amount
Promote about 4.3 times and FLG gene performance amounts and promote about 1.6 times, this as the result is shown willow herb extract of the invention have it is excellent
The ability of different promotion TGM, KRT, APQ and FLG gene performance amount, effectively can maintain skin keratinocytes to arrange, make skin angle
Matter layer structural integrity, also can effectively promote skin barrier function also can make skin form more moisturizing factors.
The willow herb extract of the invention of embodiment 3 promotes the protein expression amount of aquaporin in horn cell
The present invention further detects the performance situation of aquaporin in horn cell, by the egg of detection aquaporin
White matter performance, to learn that willow herb extract of the invention promotes the situation of horn cell water content.Firstly, by 2x103A mankind
Horn cell culture primary on the cover slip (coverslip is placed in 6 hole culture plates), and is cultivated 16 to 18 hours in 37 DEG C,
It is middle that mankind's horn cell primary is divided into two groups: (1) that the experimental group and the control of (2) blank of willow herb extract of the invention is added
Group, then with immuning fluorescent dyeing analysis (Immunofluorescence Assay) and confocal image microscope (Laser
Scanning Confocal Microscopy) the protein expression situation of aquaporin in observation horn cell primary.It will
Horn cell on coverslip fixes 15 minutes with 4% paraformaldehyde (Paraformaldehyde) of 300 μ l at room temperature, and
It is flushed three times with 500 μ l phosphate buffer solutions (Phosphate buffered saline, PBS), then contains 0.5% with 300 μ l
The phosphate buffer solution of Triton X-100 cell is perforated at room temperature (penetrate) remove ten minutes later, then plus
Enter 300 μ l blocking solution (containing 1% bovine serum albumin(BSA) (Bovine serum albumin, BSA) phosphate-buffered it is molten
Liquid) it acts on 1 hour at room temperature, to reduce the non-specific combination of impurity and antibody in subsequent experimental, and with 500 μ l phosphate
Buffer solution flushes three times, and is subsequently added into the more plants of capture antibody (Polyclonal of APQ3 of 200 μ l prepared with blocking solution
Anti-AQP3 antibody is purchased from Bosterimmunoleader, the U.S., number PA1488) solution, 2 are acted at 37 DEG C
Hour, and flushed three times with 500 μ l phosphate buffer solutions, it is subsequently added into the Alexa of 200 μ l prepared with blocking solution
Anti- mouse secondary antibody (being purchased from Thermo, the U.S., number A11032) solution of Fluor-488 coupling, it is small to act on 1 at 37 DEG C
When, and flushed three times with 500 μ l phosphate buffer solutions, the Hirst after being subsequently added into 20000 times of dilutions of 200 μ l
(Hoechst 33342 is purchased from Thermo, the U.S., number 62249) makes cell nuclear staining 3~5 minutes at room temperature, and with
500 μ l phosphate buffer solutions flush three times, and then coverslip is fixed on a glass slide, and scan in confocal laser
It is observed under microscope (ZEISS LSM 700).
The experiment of willow herb extract of the invention for protein performance amount in horn cell of promotion aquaporin
As a result as shown in figure 4, after the processing of willow herb extract, compared to blank control group, the table of the protein of aquaporin to albumen 3
Now amount is obviously improved.Willow herb extract of the invention has and excellent promotes aquaporin in horn cell as the result is shown for this
Protein expression amount, and can effectively promote the water content of horn cell and form more moisturizing factors, there is effect to promote cutin
The ability of layer structural integrity.
The willow herb extract of the invention of embodiment 4 promotes the effect of horn cell secretion sodium hyaluronate
Willow herb extract of the invention is further tested to the effect for promoting horn cell secretion sodium hyaluronate, due to known angle
Cell plastid can secrete the substances such as sodium hyaluronate as cytoplasm, to maintain the complete of epidermis barrier, and prevent moisture of skin from dissipating
Complete protection is lost and is formed, therefore.First in 96 hole culture plates, every hole is added the above-mentioned culture solution of 200 μ l and is implanted into 1x104
A horn cell, and in 37 DEG C culture 16-18 hours, cell is then divided into three groups: (1) 0.0625mg/mL or (2) are added
Willow herb extract and (3) blank control group 0.03125mg/mL of the invention, in 37 DEG C cultivate 24 hours, the time arrive after not
In the case that disturbance attaches cell, the culture solution of 120 μ l is collected in every hole.
It is analyzed followed by the ELISA of sodium hyaluronate (Human Hyaluronic Acid, HA are also known as mankind's hyaluronic acid)
Detection reagent set group (being purchased from Cusabio Biotech company, China, number CSB-E04805h) is analyzed.First in the bottom of at
Portion covers one layer of mankind's hyaluronic acid and captures in 96 hole culture plates of antibody, and the culture solution or molten that each hole of 100 μ l is collected is added
In the standard items of the phosphate buffer solution containing 1% bovine serum albumin(BSA), it is combined 2 hours at 37 DEG C with capture antibody,
Time arrive after by liquid removal, and the detecting antibody of 100 μ l is directly added in every hole, it is small to capture antibody 1 for detecting at 37 DEG C
Shi Hou, with the cleaning solution (phosphoric acid of the anhydrous sorbitan monolaurate containing 0.05% polyoxyethylene (tween 20) of 200 μ l
Salt buffer solution) rinse 96 hole culture plates in each hole altogether three times, add the horseradish peroxidase-labeled strepto- of 100 μ l
Avidin (Streptavidin-HRP) acts on 1 hour at 37 DEG C, is combined with detecting antibody, then with the clear of 200 μ l
It is total three times that dilution rinses each hole in 96 hole culture plates, and the colour generation solution of 90 μ l is added, and 15~30 are acted at 37 DEG C
Minute and be protected from light, add the stop bath of 50 μ l with stopped reaction, finally measured in its 5 minutes with ferment immunity analysis instrument
In the light absorption value of 450nm.Student t-test is carried out to determine the coefficient of variation and whether statistically have with Excel software again
There were significant differences (* p value < 0.05；* p value < 0.01；* * p value < 0.001).
Willow herb extract of the invention to promote horn cell secretion sodium hyaluronate effect experimental result as shown in figure 5,
After the processing of willow herb extract, the sodium hyaluronate amount of horn cell secretion is dramatically increased, compared to the sodium hyaluronate of blank control group
Secretory volume increases by 9.6% with the group that 0.0625mg/mL willow herb extract is handled, and with 0.03125mg/mL willow herb extract
The group of processing increases by 23.8%, and there is excellent promotion horn cell to secrete glass for willow herb extract of the invention as the result is shown for this
The ability of uric acid can effectively make keratoderma structural integrity and promote skin barrier function, and promote skin moisturizing power.
The willow herb extract of the invention of embodiment 5 soothes the skin sensitive, general red effect
To confirm willow herb extract of the invention in soothing the skin general red effect, firstly, preparation addition 1% willow herb extraction
1% willow herb Essence of object；And do not conform to the Essence of willow herb extract Essence as a control group, the wherein Essence ingredient
It is all water, fragrant fresh ketone, hexylene glycol, 1,3-BDO, Xanthan gum, thickener and triethanolamine.Then, 8 subjects are raised,
Every subject is after having cleaned face daily morning and evening, by control group Essence, containing willow herb extract Essence of the invention point
It is not used in the skin of half face of left and right, and promotion is massaged slightly with finger pulp and is absorbed, with 4 weeks after use with VISIA flesh before using
Skin detector (CIS-VISIA.7 VISIA Complexion Analysis System, Canfield scientific, beauty
State, serial number V71214) carry out heat flush skin quality detection.
Willow herb extract of the invention is to the experimental result for soothing the skin general red effect as shown in fig. 6, using this hair is contained
After the Essence of bright willow herb extract, than using control group to soothe the skin general red 7% (zero circle 91.5%, 4th week
84.5%), this willow herb extract of the invention can effectively soothe the skin general red as the result is shown, have and promote skin barrier and guarantor
The effect of wet ability.
In conclusion the willow herb extract that the present invention is extracted using water, alcohols or alcohol-water mixture by solvent, can have
Effect promoted horn cell in moisturizing related gene performance amount, promoted aquaporin protein in horn cell performance amount,
Promote horn cell secretion sodium hyaluronate effect and can effectively soothe the skin sensitivity, it is general red, to maintain skin keratinocytes to arrange,
Make keratoderma structural integrity, to promote skin barrier function and skin is made to form more moisturizing factors.Therefore, of the invention
Willow herb extract can be used for preparing willow herb extract for promoting transglutaminase gene, keratin gene, aquaporin egg
The purposes of white gene and the medical composition of poly- keratin microfilament gene performance amount, the composition can be powdered, graininess, liquid
Shape, glue or paste, and can be made into food, drink, drug, reagent or nutritional supplement, by modes such as oral, dermal applications
Give an individual.
Claims (10)
1. a kind of willow herb extract, which is used to prepare, promotes transglutaminase (Transglutaminase, TGM) gene, keratin
(Keratin, KRT) gene, aquaporin (Aquaporin, AQP) gene and poly- keratin microfilament (Filaggrin, FLG)
The purposes of the medical composition of gene performance amount, wherein the willow herb extract is obtained with one willow herb of a solvent extraction, this is molten
Agent is water, alcohol or alcohol-water mixture, and the liquid-solid ratio of the solvent and the willow herb is 5~20: 1~5, and the extraction step is 50
DEG C~100 DEG C of progress.
2. purposes according to claim 1, which is characterized in that the transglutaminase gene is transglutaminase 1
(Transglutaminase 1, TGM1) gene.
3. purposes according to claim 1, which is characterized in that the keratin gene include Keratin 1 (Keratin1,
KRT1) gene, Keratin 10 (Keratin10, KRT10) gene and Keratin 14 (Keratin14, KRT14) gene.
4. purposes according to claim 1, which is characterized in that the medical composition can maintain the arrangement of horn cell,
Make keratoderma structural integrity.
5. a kind of willow herb extract is used to prepare the medicinal combination for promoting the protein expression amount of aquaporin in horn cell
The purposes of object, wherein the willow herb extract is obtained with one willow herb of a solvent extraction, which is water, alcohol or the mixing of alcohol water
The liquid-solid ratio of object, the solvent and the willow herb is 5~20: 1~5, and the extraction step is carried out at 50 DEG C~100 DEG C.
6. purposes according to claim 1 or 5, which is characterized in that the aquaporin is aquaporin 3
(Aquaporin 3, AQP 3).
7. a kind of willow herb extract is used to prepare the purposes for promoting the medical composition of horn cell secretion sodium hyaluronate, wherein the willow
Blue extract is obtained with one willow herb of a solvent extraction, which is water, alcohol or alcohol-water mixture, the solvent and the willow herb
Liquid-solid ratio be 5~20: 1~5, and the extraction step be 50 DEG C~100 DEG C carry out.
8. a kind of willow herb extract is used to prepare the purposes for soothing the skin sensitive, general red medical composition, wherein the willow herb extracts
Taking object is obtained with one willow herb of a solvent extraction, which is water, alcohol or alcohol-water mixture, the liquid of the solvent and the willow herb
Gu than being 5~20: 1~5, and the extraction step is carried out at 50 DEG C~100 DEG C.
9. according to claim 1, purposes described in any one of 5,7 or 8, which is characterized in that the medical composition is further
Include a pharmaceutically acceptable carrier.
10. according to claim 1, purposes described in any one of 5,7 or 8, which is characterized in that the form of the medical composition
For powdered, graininess, liquid, glue or dosage form paste.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW107111692A TWI674106B (en) | 2018-04-02 | 2018-04-02 | Use of epilobium angustifolium extracts for inducing the gene expression of transglutaminase, keratin, aquaporin and filaggrin |
| TW107111692 | 2018-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110339220A true CN110339220A (en) | 2019-10-18 |
Family
ID=68173799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811315571.9A Pending CN110339220A (en) | 2018-04-02 | 2018-11-05 | Willow herb extract is used to be promoted the purposes of gene performance amount |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110339220A (en) |
| TW (1) | TWI674106B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117482020A (en) * | 2023-11-30 | 2024-02-02 | 广州茱颜化妆品有限公司 | Composition for repairing skin barrier and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003277249A (en) * | 2002-03-20 | 2003-10-02 | Noevir Co Ltd | Skin care preparation, epidermal cell activator, dermal fibroblast activator and collagen production promotor |
| JP2003342121A (en) * | 2002-05-28 | 2003-12-03 | Noevir Co Ltd | Skin care preparation |
| WO2004016236A1 (en) * | 2002-08-14 | 2004-02-26 | Fancl Corporation | Cosmetics |
| JP3693243B2 (en) * | 2001-10-29 | 2005-09-07 | 株式会社ノエビア | Whitening cosmetics |
| CN105194096A (en) * | 2015-09-21 | 2015-12-30 | 成都圣雪贝佳化妆品有限公司 | Preparation fast relieving skin red, swelling, heat, pain and itch and preparing method thereof |
-
2018
- 2018-04-02 TW TW107111692A patent/TWI674106B/en active
- 2018-11-05 CN CN201811315571.9A patent/CN110339220A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3693243B2 (en) * | 2001-10-29 | 2005-09-07 | 株式会社ノエビア | Whitening cosmetics |
| JP2003277249A (en) * | 2002-03-20 | 2003-10-02 | Noevir Co Ltd | Skin care preparation, epidermal cell activator, dermal fibroblast activator and collagen production promotor |
| JP2003342121A (en) * | 2002-05-28 | 2003-12-03 | Noevir Co Ltd | Skin care preparation |
| JP3957169B2 (en) * | 2002-05-28 | 2007-08-15 | 株式会社ノエビア | Topical skin preparation |
| WO2004016236A1 (en) * | 2002-08-14 | 2004-02-26 | Fancl Corporation | Cosmetics |
| CN105194096A (en) * | 2015-09-21 | 2015-12-30 | 成都圣雪贝佳化妆品有限公司 | Preparation fast relieving skin red, swelling, heat, pain and itch and preparing method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 向雪岑: "柳兰外用制剂在皮肤急性炎症中的应用", 《2017中国中西医结合学会医学美容专业委员会年会会议摘要》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117482020A (en) * | 2023-11-30 | 2024-02-02 | 广州茱颜化妆品有限公司 | Composition for repairing skin barrier and preparation method and application thereof |
| CN117482020B (en) * | 2023-11-30 | 2024-04-05 | 广州茱颜化妆品有限公司 | Composition for repairing skin barrier and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI674106B (en) | 2019-10-11 |
| TW201941781A (en) | 2019-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105287341B (en) | A kind of skin whitening, moisturizing Essence and preparation method thereof | |
| CN102355910B (en) | ABH antigen is utilized to improve the compositions of diseases associated with inflammation | |
| CN103222988B (en) | A kind of American-cockroach-extract and its preparation method and application | |
| CN110279602A (en) | Skin repair composition, preparation method, and the application in cosmetics | |
| CN105338991A (en) | Anti-dandruff compositions, and methods of use thereof | |
| TW200306209A (en) | Medicament for curing itching rough skin or sensitive skin and for skin whitening based on reducing production and/or release of stem cell factor | |
| CN115074393A (en) | Pichia pastoris fermentation lysate filtrate, preparation method and application | |
| CN101491485B (en) | Skin external composition containing silybin glycoside | |
| CN108703931A (en) | A kind of composition and preparation method thereof with moisture-keeping function | |
| US20110045105A1 (en) | Cosmetic use of an ophiopogon japonicus active principle | |
| CN110339220A (en) | Willow herb extract is used to be promoted the purposes of gene performance amount | |
| TWI729618B (en) | Use of phalaenopsis plant extract for anti-glycation and improving skin appearance | |
| CN103222981A (en) | Application of dendrobium candidum polysaccharide in preparing drug for promoting hair growth | |
| JP6198082B2 (en) | Sea grape extract to suppress allergies, its preparation method and application | |
| CN1569884B (en) | Method for preparing astragaloside and its use in preparation of drug for preventing and treating diabetic nephropathy | |
| CN102114170A (en) | Traditional Chinese medicine composition for preventing and treating myocardial ischemia reperfusion injury and preparation method thereof | |
| CN101664370A (en) | Eriocaulon henryanum Ruhl P.E. and application thereof in cosmetics | |
| CN116115541A (en) | Preparation method and application of soothing composition | |
| CN110179903B (en) | Application of aquilaria sinensis extract in reducing skin inflammation reaction caused by irradiation of ultraviolet light on keratinocytes and promoting skin cutin metabolism | |
| US20170007640A1 (en) | Method and system for extracting and using moomiyo compositions | |
| Nnodim | In vitro effect of Allopurinol on sickling rate and uric acid level in sickle cell erythrocyte. | |
| CN110354154A (en) | A kind of narrow-leaved oleaster polysaccharide extract can be relieved drying property scytitis and preparation method | |
| CN104958425A (en) | Medicinal composition for treating photosensitive dermatoses as well as preparation and preparation application thereof | |
| CN110946892B (en) | Application of red soybean extract in increasing gene expression amount of hyaluronic acid synthetase | |
| PECK et al. | Trichophytin: I. Methods of Preparation with Special Reference to the Specific Skin-Reactive Factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191018 |